Therefore, there is a possibility that GPX4 inhibition could lead to adverse events in normal organs and tissues, making them difficult for evaluate in a clinical study for cancer treatment in humans, and further preclinical studies with in vivo model are needed to assess the potential therapeutic triple combination treatment of the GPX4 inhibitors combined with ALK‐TKI and bypass signal inhibitors for ALK‐fusion‐positive NSCLC cells. The gene discussed is ALK; the disease is non-small cell lung carcinoma.